Yahoo Web Suche

Suchergebnisse

1. www.pumabiotechnology.comPuma Biotechnology

   www.pumabiotechnology.com

   • Im Cache

   Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011.

2. finance.yahoo.com › quote › PBYIPuma Biotechnology, Inc. (PBYI) - Yahoo Finance

   finance.yahoo.com › quote › PBYI

   • Im Cache

   21. Jan. 2022 · Find the latest Puma Biotechnology, Inc. (PBYI) stock quote, history, news and other vital information to help you with your stock trading and investing.

3. en.wikipedia.org › wiki › Puma_BiotechnologyPuma Biotechnology - Wikipedia

   en.wikipedia.org › wiki › Puma_Biotechnology

   • Im Cache

   Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.

4. investor.pumabiotechnology.com › news-releases › news-detailsPuma Biotechnology, Inc. - Puma Biotechnology Announces Exclusive...

   investor.pumabiotechnology.com › news-releases › news-details

   • Im Cache

   20. Sept. 2022 · Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and ...

5. investor.pumabiotechnology.com › news-releases › news-detailsPuma Biotechnology, Inc. - Puma Biotechnology Announces Phase II...

   investor.pumabiotechnology.com › news-releases › news-details

   • Im Cache

   11. Dez. 2023 · Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer (PUMA-ALI-1201).

6. investor.pumabiotechnology.com › news-releases › news-detailsPuma Biotechnology Announces FDA Clearance of IND for Alisertib...

   investor.pumabiotechnology.com › news-releases › news-details

   • Im Cache

   8. Aug. 2023 · Puma’s Phase II trial (Study PUMA-ALI-4201) will enroll up to 60 patients with extensive stage small cell lung cancer who have progressed after first-line platinum-based chemotherapy and immunotherapy. Patients must provide tissue-based biopsies so that biomarkers can be analyzed.

7. finance.yahoo.com › news › puma-biotechnology-announcesPuma Biotechnology Announces Presentation of Findings from a...

   finance.yahoo.com › news › puma-biotechnology-announces

   • Im Cache

   14. Okt. 2023 · LOS ANGELES, October 14, 2023--Puma Biotechnology reported findings from a Phase I/II study of Alisertib and pembrolizumab for Rb-Deficient HNSCC at the 2023 AACR-NCI-EORTC meeting.

8. Bilder

   • 
   • 

   Alle anzeigen